Mirdametinib: all 26 studies that test it
Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young AdultsNot yet recruitingNCT07891286Phase 2
- A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasNot yet recruitingNCT07850635Phase 1
- A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy ParticipantsRecruitingNCT07840612Phase 1
- A Study of Mirdametinib in People With Central Nervous System TumorsRecruitingNCT07539441Phase 1/2
- Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade GliomaNot yet recruitingNCT07521657Phase 2
- Mirdametinib in Patients With Advanced NF1-mutant MelanomaRecruitingNCT07237100Phase 2
- Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic LeukemiaRecruitingNCT07061951Phase 2
- Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibRecruitingNCT06997276Phase 1
- A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaRecruitingNCT06843967Phase 1/2
- A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]RecruitingNCT06693284Early Phase 1
- Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPKRecruitingNCT06666348Phase 1/2
- Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).RecruitingNCT06159166Phase 1/2
- Mirdametinib in Histiocytic DisordersRecruitingNCT06153173Phase 2
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsRecruitingNCT05983159Phase 2
- SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade GliomaRecruitingNCT04923126Phase 1/2
- Mirdametinib + BGB-3245 in Advanced Solid TumorsTerminatedNCT05580770Phase 1/2Results posted
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasActive, not recruitingNCT03962543Phase 2Results posted
- MEK and MET Inhibition in Colorectal CancerCompletedNCT02510001Phase 1Results posted
- MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1CompletedNCT02096471Phase 2Results posted
- To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy ParticipantsCompletedNCT07279233Phase 1
- Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple MyelomaSuspendedNCT06876142Phase 1/2
- Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid TumorsCompletedNCT03905148Phase 1
- Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCCompletedNCT02039336Phase 1/2
- PALBOCICLIB + PD-0325901 for NSCLC & Solid TumorsCompletedNCT02022982Phase 1
- MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung CancerTerminatedNCT00174369Phase 2
- MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.TerminatedNCT00147550Phase 1/2